Fremanezumab in individuals with chronic migraine who had inadequate response to onabotulinumtoxinA and topiramate or valproic acid.

ABSTRACT:

SUBMITTER: Ferrari MD 

PROVIDER: S-EPMC9322527 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature